期刊文献+

大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展 被引量:2

Application of high-dose intravenous immunoglobulin therapy in severe dermatoses
原文传递
导出
摘要 大剂量静脉注射免疫球蛋白(IVIG)在部分难治性和危重皮肤病的治疗中疗效肯定,不良反应少。IgG的Fab段和Fc段可以通过结合各种自身抗原、自身抗体、补体等来介导特定的下游效应,以达到抗炎效果。该文综述IVIG的治疗机制,其在重症药疹、难治性皮肌炎和自身免疫性大疱病等重症皮肤病中的应用,以及特殊人群使用和不良反应等。 High-dose intravenous immunoglobulin(IVIG)has emerged as an effective treatment option for some refractory and severe dermatoses with few adverse reactions.The Fab and Fc fragments of IgG can exert anti-inflammatory effect by mediating specific downstream reactions via binding to a variety of autoantigens,autoantibodies and complements.This review summarizes action mechanisms of IVIG,focuses on the progress towards its application in severe dermatoses(such as severe drug eruption,refractory dermatomyositis and autoimmune bullous diseases)and special populations,as well as its adverse reactions.
作者 李丹琪 楼雨晨 陶娟 Li Danqi;Lou Yuchen;Tao Juan(Department of Dermatology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Center of Skin Recovery and Theranostics,Wuhan 430022,China)
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2022年第5期455-459,共5页 Chinese Journal of Dermatology
基金 国家自然科学基金(81974245)。
关键词 免疫球蛋白类 静脉内 皮肤疾病 重症皮肤病 Immunoglobulins intravenous Skin diseases Severe dermatoses
  • 相关文献

参考文献5

二级参考文献47

  • 1陈喜雪,朱学骏.天疱疮及大疱性类天疱疮的治疗[J].继续医学教育,2006,20(23):54-56. 被引量:15
  • 2Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129 ( 1 ): 92-96.
  • 3Bastuji-Garin S, Fouchard N, Bertocehi M, et al. SCORTEN: a severity of illness score for toxic epidermal neerolysis. J Invest Dermatol, 2000, 115(2): 149-153.
  • 4Imahara SD, Holmes JH, Heirnbaeh DM, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res, 2006, 27(3 ): 270-275.
  • 5Cartotto R, Mayich M, Nickerson N, et al. SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Neerolysis Patients Treated in a Burn Center. J Bum Care Res, 2008, 29 (1): 141-146.
  • 6Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN During the First Five Days of Hospitalization to Predict the Prognosis of Epidermal Necrolysis. J Invest Dermatol, 2006, 126(2): 272-276.
  • 7Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol, 2004, 140(7): 890- 892.
  • 8Liddell FD. Simple exact analysis of the standardized mortality ratio. J Epidemiol Community Health, 1984, 38( 1 ): 85-88.
  • 9Khalili B, Bahna SL. Pathogancsis and recent therapoutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol, 2006, 97(3 ): 272-280.
  • 10Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal neerolysis; 15 years' experience in a Dutch bums centre. J Ettr Aead Dermatol Venereol, 2007, 21(6): 781-788.

共引文献553

同被引文献37

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部